3-Deschloro-4-desfluoro-4-chloro-3-fluoro Gefitinib

3-Deschloro-4-desfluoro-4-chloro-3-fluoro Gefitinib, also known as AZD9291, is a small molecule inhibitor used in the treatment of non-small cell lung cancer (NSCLC). It is a third-generation epidermal growth factor receptor (EGFR) inhibitor that targets mutated forms of EGFR that are resistant to first and second-generation EGFR inhibitors. This drug acts by binding to the ATP-binding site of the EGFR tyrosine kinase, thereby inhibiting the phosphorylation of downstream signaling molecules and ultimately leading to cell cycle arrest and apoptosis. Chemically, 3-Deschloro-4-desfluoro-4-chloro-3-fluoro Gefitinib is a synthetic derivative of Gefitinib, with the addition of a chlorine and fluorine atom to the molecule. The molecular formula of this drug is C27H33ClFN7O3, and it has a molecular weight of 567.06 g/mol. It is a white to off-white powder that is sparingly soluble in water and slightly soluble in ethanol. The recommended dose of 3-Deschloro-4-desfluoro-4-chloro-3-fluoro Gefitinib is 80 mg once daily, administered orally with or without food. The drug is metabolized in the liver and excreted primarily in the feces. It is important to note that this drug can cause several side effects, including diarrhea, rash, nausea, and fatigue. Therefore, patients receiving this drug should be closely monitored for any adverse effects. In conclusion, 3-Deschloro-4-desfluoro-4-chloro-3-fluoro Gefitinib is an effective and targeted drug used in the treatment of NSCLC, and its chemical properties and recommended usage should be closely considered by healthcare professionals.